A weight-losing outlier in the phase III trial's placebo group "should have been picked up earlier or should have been thrown out before we unblinded," Opko Health Inc.'s vice president, Steven Rubin, told BioWorld Today, and that anomaly, with potentially others, changed an otherwise-positive outcome with long-acting human growth hormone hGH-CTP in adults with growth hormone deficiency.